Vallon Pharmaceuticals Inc., headquartered in Philadelphia, is an emerging pharmaceutical company focused on the development of new medications to help patients with central nervous system (CNS) disorders. The company’s lead product candidate is an abuse deterrent formulation of amphetamine immediate release (ADAIR) for the treatment of ADHD and Narcolepsy. There is substantial unmet need for abuse deterrent psychostimulants, given that over 5 million Americans misuse Rx stimulants annually and over 40% of abusers/misusers do so by non-oral routes of administration, predominately by snorting. The ADAIR program is phase III ready. Vallon will begin conducting human abuse liability clinical trials of ADAIR in 1H 2019.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
ADAIR (Abuse Deterrent Amphetamine Immediate Release)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):